Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 2

16:13 EST 21st February 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 26–50 of 6,200+

Relevant

Abeona Therapeutics Inc: Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium

NEW YORK and CLEVELAND, 2018-02-02 14:45 CET (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...


CSE: 2017-1012 - Delist - Pivotal Therapeutics Inc. (PVO)

TORONTO, ONTARIO -- (Marketwired) -- 10/23/17 -- The common shares of Pivotal Therapeutics Inc. will be delisted at the market close today, October 23, 2017. Pivotal Therapeutics is currently susp...

CanniMed Therapeutics: Ring frei!

Aurora Cannabis Inc. will den kanadischen Mitbewerber CanniMed Therapeutics schlucken. Das Management von CanniMed Therapeutics zeigte sich mit Blick auf die "Aurora-Offerte" nur mäßig erfreut. Ein...


Trillium Therapeutics Inc.: Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter

TORONTO, ONTARIO -- (Marketwired) -- 02/09/18 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of ...

CureVac and Arcturus Collaborate to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

TÜBINGEN, Germany & BOSTON & SAN DIEGO–(BUSINESS WIRE)–CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messe...

Spark Therapeutics, Inc.: Spark Therapeutics nimmt an mehreren Konferenzen im Januar teil

PHILADELPHIA (USA), 3. Januar 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar...

Silence Therapeutics sells more of its holding in Arrowhead

RNA-based therapeutics discovery and development company Silence Therapeutics has sold a further part of its holding of common shares in Arrowhead Pharmaceuticals, it announced on Monday. The AIM-t...

Crestovo, Finch Therapeutics merge to create fully-integrated microbiome company

Finch Therapeutics Inc. is merging with fellow closely held microbiome company Crestovo to form Finch Therapeutics Group.

Knight Therapeutics Inc. and SIFI S.p.A: Knight Therapeutics and SIFI S.p.A. Announce Filing of New Drug Submission for NETILDEX in Canada

MONTREAL, QUEBEC -- (Marketwired) -- 02/15/18 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, and S.I.F.I- Societa Industria Farmaceutica Ita...

Probably Relevant

CRISPR Therapeutics’ Lundberg Steps Down as Chief Scientific Officer

Bill Lundberg is leaving his position as chief scientific officer of CRISPR Therapeutics (NASDAQ: CRSP). CRISPR Therapeutics, which has operations in Switzerland and Cambridge, MA, said that Lundberg will continue as an advisor to the company and he is now head of its scientific advisory board. CRISPR Therapeutics develops treatments based on the CRISPR-Cas9 gene […]

Evox Therapeutics Appoints Antonin de Fougerolles as Chief Executive Officer

Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Dr Antonin "Tony" de Fougerolles as Read more...

ProQR licenses LUMC's antisense therapeutics IP for amyloid-beta-mediated diseases

Dutch RNA-based therapeutics start-up ProQR Therapeutics NV licensed exclusive worldwide rights to Leiden University Medical ...

Quotidian Technical Highlights on Selected Biotech Stocks -- Voyager Therapeutics, Cambrex, ...

www.wallstequities.com/registration Voyager Therapeutics Cambridge, Massachusettsheadquartered Voyager Therapeutics Inc.'s shares recorded a trading volume of 212,557 shares last Friday. The stock finished the trading session Read more...

What Is Digital Therapeutics; Examples of an App That Is Gaining Attention

I had never heard the term digital therapeutics until I encountered a recent article that used the term (see: Digital Therapeutics: The Future of Health Care Will Be App-Based). Below is an excerpt from it: Last month, healthcare startup Omada Health secured a $50 million C round led by major...

Active-Investors: Blog Exposure - InVivo Therapeutics Signs Share Repurchase Agreement with Lincoln Park Capital

LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) ("InVivo Therapeutics"). If you want ...

Siamab and BI agree to collaborate on development of antibody therapeutics for solid tumors

Siamab Therapeutics Inc. and Boehringer Ingelheim GMBH are collaborating to develop antibody therapeutics targeting tumor ass...

RNA as a Therapy: Reviewing the Future Generation of Therapeutics

You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that some believe could be as big a revolution as monoclonal ... This awesome article RNA as a Therapy: Reviewing the Future Generation of Therapeutics appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

miRagen Therapeutics Announces Five Presentations at the DIA Oligonucleotide-Based Therapeutics Conference

BOULDER, Colo., Oct. 18, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that clinical data for its two lead product candidates, MRG-106 and MRG-201, will be presented at the DIA Oligonucleotide-Based Therapeutics Conference. The conference is being...

Spark Therapeutics, Inc.: Spark Therapeutics veranstaltet am Dienstag, 20. Februar, um 8.30 Uhr ET eine Telefonkonferenz, um über die Ergebnisse des Jahres 2017 und über aktuelle geschäftliche Höhepunkte zu sprechen

PHILADELPHIA, 13. Februar 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sin...

Boehringer partners with UK’s Autifony for CNS therapeutics

UK-based biotechnology firm Autifony Therapeutics has entered an agreement with Boehringer Ingelheim regarding select aspects of its Kv3.1/3.2 voltage-gated potassium...Read More... The post Boehringer partners with UK’s Autifony for CNS therapeutics appeared first on Pharmaceutical Technology.

Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus’s LUNAR™ li...

Acer Therapeutics and Opexa Therapeutics Close Merger and Financing

-Merger to create a pre-NDA-stage, Nasdaq-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need- -Combined company, renamed Acer Therapeutics Inc., to commence trading on Nasdaq under the symbol “ACER” on September 21- -Concurrent financing of $15.7 million from Acer investor syndicate- -Ac...

Addex Therapeutics: Addex Therapeutics Equity Research Report Update Issued by valuationLAB

Addex Therapeutics / Addex Therapeutics Equity Research Report Update Issued by valuationLAB . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the cont...

The Current issue of “The view from here” is concerned with Novel Therapeutics.

The topic of this month’s newsletter from Drug Discovery Today is Novel Therapeutics.

VIDEO: Mission Therapeutics CEO On Clinical Strategy For DUB Drugs

Anker Lundemose, CEO of UK-based Mission Therapeutics, outlines the company's emerging DUBs drug discovery platform on the sidelines of the...   


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks